13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001848809
Total reported value
$164.2M
$164.2M
46 檔
54.4%
As reported in its official Q4 2025 Form 13F filing, Velan Capital Investment Management LP's tracked investment portfolio stood at $164.2M with 46 total positions.
Velan Capital Investment Management LP executed strategic sector rebalancing during Q4 2025, establishing 9 new positions while fully exiting 12 holdings and trimming 5 positions.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, CDTX, TARA) accounted for 54.4% of total reported equity market value during Q4 2025.
Top New Position Initiated
MPLT
市值: $9.2M
Top Position Liquidated / Trimmed
前期市值: $4.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 17.23% | -2.24% | -24.11% | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 13.89% | — | — | |
| 3 | TARA | Protara Therapeutic Inc | Stock-Other | 8.76% | -2.63% | +32.52% | |
| 4 | HRTX | Heron Therapeutics Inc | Stock-Other | 6.60% | -2.11% | — | |
| 5 | MPLT | Maplight Therapeutics Inc | Stock-Other | 5.32% | +4.48% | — | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 5.24% | -0.04% | +4.05% | |
| 7 | EVMN | Evommune Inc | Stock-Other | 5.03% | -2.78% | — | |
| 8 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 3.18% | -0.01% | -14.01% | |
| 9 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 2.88% | — | +1.55% | |
| 10 | JSPR | Jasper Therapeutics Inc | Stock-Other | 2.83% | -0.78% | — | |
| 11 | AVTX | Avalo Therapeutics Inc | Stock-Other | 2.78% | +1.92% | — | |
| 12 | ESPR | Esperion Therapeutics Inc | Stock-Other | 2.60% | -2.95% | EXIT | |
| 13 | VRCA | Verrica Pharmaceuticals Inc | Stock-Other | 2.27% | +0.20% | — | |
| 14 | NSPR | Inspiremd Inc | Stock-Other | 2.21% | -2.08% | — | |
| 15 | RAPT | Rapt Therapeutics Inc | Stock-Other | 2.12% | — | +35.04% | |
| 16 | STRO | Sutro Biopharma Inc | Stock-Other | 2.09% | +2.37% | — | |
| 17 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.64% | — | +250.00% | |
| 18 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.58% | -0.02% | — | |
| 19 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.56% | -1.01% | — | |
| 20 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 1.54% | -0.18% | — | |
| 21 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.49% | — | — | |
| 22 | PROF | Profound Medical CORP | Stock-Other | 1.30% | -0.47% | — | |
| 23 | KZIA | Kazia Therapeutics-spon Adr | Stock-Other | 1.20% | -0.63% | EXIT | |
| 24 | RZLT | Rezolute Inc | Stock-Other | 1.03% | +0.95% | — | |
| 25 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.59% | -0.36% | — | |
| 26 | EDSA | Edesa Biotech Inc | Stock-Other | 0.57% | +1.39% | — | |
| 27 | ✓ | Trevi Therapeutics Inc | Stock-Other | 0.28% | — | — | |
| 28 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.25% | -0.26% | EXIT | |
| 29 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.21% | — | — | |
| 30 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.20% | -1.32% | — | |
| 31 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.19% | +0.04% | — | |
| 32 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.18% | +0.08% | — | |
| 33 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.15% | -0.01% | — | |
| 34 | GOSS | Gossamer Bio Inc | Stock-Other | 0.13% | — | — | |
| 35 | IMNM | Immunome Inc | Stock-Other | 0.12% | -0.01% | — | |
| 36 | DSGN | Design Therapeutics Inc | Stock-Other | 0.11% | -0.13% | EXIT | |
| 37 | IMMX | Immix Biopharma Inc | Stock-Other | 0.11% | +2.59% | — | |
| 38 | CNTX | Context Therapeutics Inc | Stock-Other | 0.09% | -0.14% | — | |
| 39 | REPL | Replimune Group Inc | Stock-Other | 0.08% | +0.03% | -25.00% | |
| 40 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.07% | -0.03% | — | |
| 41 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 42 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.06% | — | -78.69% | |
| 43 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.05% | — | — | |
| 44 | DTIL | Precision Biosciences Inc | Stock-Other | 0.05% | +0.05% | — | |
| 45 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.03% | — | -27.27% | |
| 46 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.03% | -0.06% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | +10.6% | -24.11% | Trim |
| 2 | CDTX | Cidara Therapeutics Inc | +4.1% | — | Unchanged |
| 3 | 430 | Terns Pharmaceuticals Inc | +1.5% | +250.00% | Add |
| 4 | RAPT | Rapt Therapeutics Inc | +0.2% | +35.04% | Add |
| 5 | ABVX | Abivax Sa-adr | +0.1% | +4.05% | Add |
| 6 | VTYXUSD | Ventyx Biosciences Inc | +0.1% | — | Unchanged |
| 7 | ARWR | Arrowhead Pharmaceuticals In | 0% | — | Unchanged |
| 8 | NRIX | Nurix Therapeutics Inc | 0% | — | Unchanged |
| 9 | IMMX | Immix Biopharma Inc | 0% | — | Unchanged |
| 10 | TARA | Protara Therapeutic Inc | 0% | +32.52% | Add |
| 11 | IMNM | Immunome Inc | 0% | — | Unchanged |
| 12 | REPL | Replimune Group Inc | — | -25.00% | Trim |
| 13 | CNTX | Context Therapeutics Inc | — | — | Unchanged |
| 14 | TENX | Tenax Therapeutics Inc | 0% | — | Unchanged |
| 15 | PMVP | Pmv Pharmaceuticals Inc | 0% | — | Unchanged |
| 16 | DSGN | Design Therapeutics Inc | 0% | — | Unchanged |
| 17 | LRMR | Larimar Therapeutics Inc | 0% | — | Unchanged |
| 18 | CTMX | Cytomx Therapeutics Inc | 0% | — | Unchanged |
| 19 | PTGX | Protagonist Therapeutics Inc | 0% | — | Unchanged |
| 20 | GOSS | Gossamer Bio Inc | 0% | — | Unchanged |
| 21 | ✓ | Proqr Therapeutics N.v. | 0% | — | Unchanged |
| 22 | OVID | Ovid Therapeutics Inc | -0.1% | — | Unchanged |
| 23 | DTIL | Precision Biosciences Inc | -0.1% | — | Unchanged |
| 24 | PYXS | Pyxis Oncology Inc | -0.1% | -27.27% | Trim |
| 25 | VRDN | Viridian Therapeutics Inc | -0.2% | — | Unchanged |
| 26 | TRVI | Trevi Therapeutics Inc | -0.3% | — | Unchanged |
| 27 | SNDX | Syndax Pharmaceuticals Inc | -0.3% | — | Unchanged |
| 28 | AVTX | Avalo Therapeutics Inc | -0.4% | — | Unchanged |
| 29 | EPRX | Eupraxia Pharmaceuticals Inc | -0.4% | — | Unchanged |
| 30 | LNTH | Lantheus Holdings Inc | -0.7% | +1.55% | Add |
| 31 | CRBP | Corbus Pharmaceuticals Holdi | -0.7% | -78.69% | Trim |
| 32 | EDSA | Edesa Biotech Inc | -1% | — | Unchanged |
| 33 | NSPR | Inspiremd Inc | -2.6% | — | Unchanged |
| 34 | JSPR | Jasper Therapeutics Inc | -3% | — | Unchanged |
| 35 | MLYS | Mineralys Therapeutics Inc | -3.1% | -14.01% | Trim |
| 36 | HRTX | Heron Therapeutics Inc | -3.8% | — | Unchanged |
| 37 | RZLT | Rezolute Inc | -5.6% | — | Unchanged |
| 38 | MPLT | Maplight Therapeutics Inc | — | NEW | New buy |
| 39 | EVMN | Evommune Inc | — | NEW | New buy |
| 40 | ESPR | Esperion Therapeutics Inc | — | NEW | New buy |
| 41 | ✓ | — | EXIT | Sold out | |
| 42 | VRCA | Verrica Pharmaceuticals Inc | — | NEW | New buy |
| 43 | ALMS | Alumis Inc | — | EXIT | Sold out |
| 44 | STRO | Sutro Biopharma Inc | — | NEW | New buy |
| 45 | STRO | Sutro Biopharma, Inc. | — | EXIT | Sold out |
| 46 | PROF | Profound Medical CORP | — | NEW | New buy |
| 47 | KZIA | Kazia Therapeutics-spon Adr | — | NEW | New buy |
| 48 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 49 | TELA | Tela Bio Inc | — | EXIT | Sold out |
| 50 | ELDN | Eledon Pharmaceuticals Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Velan Capital Investment Management LP reported a total U.S. public equity portfolio value of $164.2M across 46 disclosed positions in Q4 2025.
During Q4 2025, Velan Capital Investment Management LP's top holdings by market value included PRAX (17.2%)、CDTX (13.9%)、TARA (8.8%). The largest single position, PRAX, represented 17.2% of total portfolio value.
In Q4 2025, Velan Capital Investment Management LP made 31 total portfolio adjustments, initiating 9 new buys, adding to 5 positions, trimming 5 holdings, and fully liquidating 12 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.